A fully approved COVID-19 vaccine, clinical advances of pandemic antibodies and multibillion-dollar deals appear to be the driving forces of increasing biopharma stock prices. BioWorld’s Biopharmaceutical Index is tracking ahead by 10.6% this year, after several months of negative numbers.
Biopharma company deals with nonprofit entities, as well as grants, are not keeping the same pace as last year, but the proportion of money flowing into COVID-19 efforts continues to account for the majority of those recorded overall.
RSS
